Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Seeding Seedling

This article was originally published in Start Up

Executive Summary

The Massachusetts-based Seedling Enterprises Inc. works with inventors who have ideas but don't know how to make them commercially viable. It selects the most promising ones, develops them, and, rather than forming a company, shops them around to potential device acquirers. Venture capitalists typically aren't interested because their targeted markets are too small. While the products may be niche, the returns, theoretically, can be pretty good--almost as good as VC returns, says co-founder Josh Tolkoff.

You may also be interested in...



New EU Filings

Omaveloxolone, Reata Pharmaceuticals’s orphan drug for treating patients with Friedreich’s ataxia, is among the latest drugs that have been filed for review by the European Medicines Agency for potential EU marketing approval.

UK Guidance Tackles Social Media ‘Compliance Headache’ For Pharma

Announcing product milestones and liking LinkedIn posts are just some of the topics addressed in a long-awaited guidance that deals with the challenges prescription drug makers face in the UK when using social media.

FDA Urged To Collaborate With USPTO On Orange Book Listings, Eliminate Patent Use Codes

Stakeholders suggest a variety of USPTO and FDA actions that could help ensure patents do not improperly delay generic and biosimilar competition.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037152

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel